Nuvation Bio Inc. reported $170M of revenue over the trailing twelve months, +1084% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $170M (to Q2 2026). Net income: −$150M, trailing twelve months to Q2 2026. Free cash flow: −$217M, trailing twelve months to Q2 2026. Operating margin: −167%, trailing twelve months to Q2 2026.

NUVBNuvation Bio Inc.

Healthcare

$5.00+55% 1Y

$5.00

$3.0152 weeks$9.54

NUVB as reported

Nuvation Bio Inc. reported $170M of revenue over the trailing twelve months, +1084% on the year before. 10 reported series are charted on this page, each one as filed.

$170M

Revenue, trailing twelve months · to Q2 2026 · +1084% against the twelve months before

Net income: −$150M
Net income · −26% year on year · trailing twelve months to Q2 2026
Free cash flow: −$217M
Free cash flow · +29% year on year · trailing twelve months to Q2 2026
Operating margin: −167%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for NUVB, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$170M	+1084%	Q2 2026
Net income	−$150M	−26%	Q2 2026
EPS	−$0.44	−8.3%	Q2 2026
Gross margin	45%	n/a	Q3 2025
Operating margin	−167%	n/a	Q2 2026
Net margin	−176%	n/a	Q2 2026
ROE	−60%	n/a	Q2 2026
ROA	−29%	n/a	Q2 2026
ROIC	87%	n/a	Q2 2026
Free cash flow	−$217M	+29%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.